血必净治疗心肺复苏后继发性脑损伤的临床研究

Clinical study of Xuebijing in treatment of secondary brain injury after cardiopulmonary resuscitation

目的 观察血必净治疗心肺复苏后继发性脑损伤的临床疗效.方法 选择心肺复苏术后患者31例,按随机数字表法分为常规治疗组15例和血必净组16例.两组患者入院后均给予常规治疗,血必净组在常规治疗的基础上加用血必净治疗7d.比较两组患者心肺复苏后第1、3、5、7天血清S-100β蛋白和NSE的水平及格拉斯哥昏迷评分（GCS）评分.结果 与常规治疗组相比,血必净组血清S-100β蛋白和NSE水平在心肺复苏后各时间点均明显降低（P＜0.05）,第5、7天GCS评分明显增高（P＜0.05）.结论 血必净能降低心肺复苏术后患者血清S-100β蛋白和NSE的水平,减轻心肺复苏后的继发性脑损伤,改善脑功能.

Objective To evaluate the curative effect of Xuebijing on secondary brain injury after cardiopulmonary resuscitation（CPR）.Methods Thirty-one patients after CPR were randomly divided into the conventional treatment group （15 cases） and Xuebijing group （16 cases）.Two groups were given conventional treatment;while in the Xuebijing group,Xuebijing injection was additionally given for consecutive 7 days.The serum S-100β protein and NSE levels and Glasgow Coma Scale（GCS） score at 1,3,5,7 days after CPR were compared.Results The serum S-100β protein and NSE levels were significantly lower in the Xuebijing group at 1,3,5,7 days after CPR（P ＜0.05） ; Compared with the Conventional treatment group,GCS score was significantly higher in the Xuebijing group at 5,7 days after CPR（P ＜0.05）.Conclusions Xuebijing can reduce the serum S-100β protein and NSE level in patients after CPR,and alleviate secondary brain injury after CPR,improving brain function.